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Abstract: Pathogenic Escherichia coli (E. coli ) is severely threatening the rabbit industry in China, and the 
concern over antibiotic-resistant bacteria has given rise to an urgent need for antibiotic alternatives. In this 
study, a member (ZRP1) of the Myoviridae family was isolated from rabbit faeces using a strain of rabbit 
atypical enteropathogenic E. coli (ZR1) as host. The one-step growth curve indicated that the latent period 
was around 25 to 30 min and the burst size was 144±31 plaque-forming unit/cell. The rate of phage-resistant 
mutation was 7×10–5±4×10–5. When the bacteriophage input at the multiplicity of infection (MOI) was 0.1, 1 or 
10, the growth of host E. coli in broth was inhibited for 5 h. A single intravenous injection of ZRP1 at MOI 0.1, 
1 or 10 significantly prolonged the survival time of rabbits which simultaneously received a lethal dose of ZR1. 
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INTRODUCTION
The number of commercial rabbits raised in China is the highest in the world. Based on the FAOSTAT data, the 
production quantity of rabbit meat of China was 727 000 tons and accounted for more than 40% of the world’s total 
production in 2013. However, development of the Chinese rabbit industry is hindered by some infectious diseases 
in rabbit, including bacterial enteritis and diarrhoea. Pathogenic Escherichia coli strains were reported to be isolated 
frequently from diarrhoeic rabbits (Penteado et al., 2002) and often have a fatal effect on rabbits.
Antimicrobial drugs have been used to cure bacterial infection of animals, but the abuse and misuse of antibiotics 
resulted in the emergence of drug resistant bacteria. Because research into new antibiotics was scarce in European 
Union and United States (Wittebole et al., 2014), widespread appeals for alternatives to antibiotics have been voiced 
(Cunha et al., 2017).
Bacteriophages or phages are viruses that can kill host bacteria in a different way from antibiotics. The first successful 
application of phage therapy dates back nearly 100 yr, but it was soon eclipsed by the advent of antimicrobial agents 
(Chan et al., 2013). However, over the last two decades, phage therapy has been reconsidered as a potentially viable 
alternative to antibiotics and the UK government was encouraging its development in 2000 (Henein, 2013). By now, 
there were some works in the literature that described the characteristics of bacteriophages (Chibani-Chennoufi et al., 
2004; Jamalludeen et al., 2007) or the efficacy of bacteriophages applied in livestock and poultry (Huff et al., 2005; 
Zhang et al., 2015), but similar works in the field of rabbit industry were notably absent.
The aim of this study was to isolate and identify a pathogenic E. coli strain from a diarrhoeic rabbit and its specific 
bacteriophage. Experiments in vitro and in vivo were carried out to assess whether the lytic bacteriophage has the 
potential for controlling the infection of this pathogenic E. coli in rabbits.
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MATERIALS AND METHODS
Isolation and identification of pathogenic E. coli
One pathogenic E. coli strain (ZR1) was isolated from the liver of a dead rabbit which came from a diarrhoea-prevalent 
commercial rabbit farm in Yuyao, Zhejiang Prov., China. Genome of ZR1 was extracted by QIAamp DNA mini kit 
(QIAGEN, Germany) and 2 multiplex polymerase chain reaction (PCR) were conducted to detect virulence genes 
(eaeA, bfpA, stx1, stx2, ipaH, ST, LT and aatA) of the purified strain with a 16S rRNA PCR as control (Chacon-J. et al., 
2012). The serogroup of E. coli ZR1 was assessed with 17 O antisera, including O1, O18, O26, O44, O55, O86, O88, 
O111, O114, O119, O125, O127, O128, O142, O146, O151 and O158 (Tianjin Biochip Corporation, China). The 
susceptibility to 17 (see Table 1) antimicrobials (Hangzhou Microbial Reagent Co., Ltd., China) was tested by Kirby-
Bauer disc diffusion test following the procedure of CLSI M100-S25. Biochemical reactions including VP test, H2S 
test, utilisations of citrate, lactose, sucrose and D-sorbitol were tested by commercial methods (Hangzhou Microbial 
Reagent Co., Ltd., China) according to the specifications.
Bacteriophage isolation and purification
Approximately 2 kg of rabbit faeces were collected from the farm and suspended in sterile saline buffer for 10 min. 
The mixture was then filtered through sterile gauze followed by centrifuging for 20 min at 8000×g. One mL of the 
supernatant was added to 5 mL of tryptic soya broth (TSB; Oxoid Ltd., UK) with E. coli ZR1 and incubated overnight 
at 200 rpm and 37°C. The culture was clarified by centrifugation (20 min; 8000×g) and then passed through a 
0.22 μm filter (Surevent®, Merck Millipore, USA). The filtrate was properly diluted to examine whether it contained 
bacteriophages by the double-layer agar method (Zhang et al., 2013). Plaques appearing on the plate were stabbed 
with a tip and eluted in 0.1 mL PBS. Each bacteriophage sample was serially amplified and isolated for 5 times by 
the method mentioned above. However, only one phage named ZRP1, which formed the clearest and biggest plaque, 
was selected for further study.
Electron microscopy
A droplet of the concentrated bacteriophage 
ZRP1 suspension (1×1010 plaque-forming units [PFU]/mL) 
was applied to a Formvar-carbon-coated copper grid for 
10 min. Excess liquid was then removed by a piece of 
filter paper. The remaining sample on the grid was dyed 
with 2% phosphotungstic acid (PTA) and examined in a 
Philips CM100  transmission electron microscope (TEM) 
at a voltage of 80 kV. 
One-step growth curve
One hundred μL of phage ZRP1  (5×107  PFU/mL) was 
added to 0.9 mL of log-phase E. coli ZR1 (5×107 CFU/mL) 
suspension and allowed to absorb for 10 min at 37°C. Then 
it was transferred to a tube with 9 mL of ZRP1 antiserum 
dilution (1:10) and left to stand for 5 min to neutralise 
the free phages. The ZRP1 antiserum was prepared by 
hypodermic injection of 1 mL purified phage suspension 
(>1×1010 PFU/mL) into a healthy laboratory rabbit weekly 
for 4 wk. Blood was taken from the marginal ear vein and 
centrifuged for collecting serum after coagulation. After 
that, the mixture was diluted by 400 times and incubated 
at 37°C with shaking at 200  rpm. Aliquots were taken 
at 10  (or  5) min intervals. Titre of each sample was 
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measured immediately by the double-layer agar method. Burst size is the ratio of the plaque count at the plateau 
phase to the plaque count at latent phase (Zhang et al., 2013). The trial was repeated for 2 times and averages were 
calculated.
Determination of the phage-resistant mutant rate
Six sets of 50 μL of E. coli ZR1 culture which contained 109, 108, 107, 106, 105 and 104 colony forming units (CFU) 
each were mixed with 50 μL ZRP1 stock solution (1×1011 PFU/mL) respectively and stored in 37°C for 10 min to allow 
absorption. The mixture was poured over a tryptone soya agar (TSA; Oxoid Ltd., UK) plate surface. After incubation 
overnight at 37°C, isolated colonies that were considered bacteriophage-insensitive mutants were counted. The 
frequency of emergence of phage-resistant mutants was calculated as the ratio of the number of surviving colonies 
to the number of original E. coli (O’Flynn, et al., 2004; Pouillot, et al., 2012). All assays were performed in triplicate.
Bacteriostasis of phage at different MOIs in vitro
Bacteriophage ZRP1 and log-phase host E. coli ZR1 suspensions were mixed to set the multiplicity of infection (MOI) 
at 10, 1, 0.1, and 0.01, and the final concentration of bacterial cells was 1×108 CFU/mL. Each MOI group had 
3 replicates. Mixed suspensions were incubated at 37°C with shaking of 200 rpm for 7 h and aliquots were taken at 
1 h interval. The OD600 of samples were measured and recorded by a multifunctional microplate reader (Spectramax
® 
M5, Molecular Devices, LLC., USA). In this study, a ZR1 culture (1×108 CFU/mL) without phages was used as the 
control group. Data were analysed by One-Way ANOVA of SPSS 17.0 and least significant difference (LSD) was used 
as post-hoc multiple comparisons.
Protection against E. coli experimental infection in rabbits
Thirty-two 5-week-old rabbits with an average weight of 0.88 kg were equally assigned to 4 groups. The rabbits were 
injected via marginal ear vein with bacteriophage ZRP1 at different MOIs (10, 1 and 0.1) or sterile saline (Control), 
respectively, immediately after they received a lethal dose of E. coli ZR1 (1×1010 CFUs) via intravenous injection. 
Deaths of experimental rabbits were observed and recorded every hour after infection. Necropsy of each dead rabbit 
was performed and E. coli was re-isolated from livers of dead rabbits by MacConkey agar. Re-isolated E. coli was 
identified by multiple PCR and biochemical reactions as mentioned above. The statistical software SPSS 17.0 was 
used to analyse data by Kaplan-Meier method of Survival analysis.
Ethics
All animal studies were performed according to the 
National Institutes of Health Guidelines for the Care and 
Use of Laboratory Animals (NIH publication No. 85-23, 
revised 1996) and were approved by the Animal Care 
and Use Committee of Institute of Animal Husbandry and 
Veterinary Science, Zhejiang Academy of Agricultural 
Sciences.
RESULTS
Characteristics of E. coli ZR1
The purified bacteria formed small round red colonies on 
MacConkey agar. The detection of 16S ribosomal RNA 
gene of E. coli (V3 and V6 regions) was positive, but only 
a 384 bp band representing eaeA gene emerged on the 
gel when 2 multiplex PCR were performed (Figure 1). E. 
coli  ZR1 did not agglutinate with 17  sorts of common 
Figure 1: Multiplex PCR and 16S rRNA PCR of E. coli 
ZR1 and a typical EPEC strain (CVCC 1396).  Lane M1, 
DL 500 DNA marker (Takara); Lane M2, DL 1000 DNA 
marker (Takara); Lane 1, ZR1 (eaeA+, 384bp); Lane 2, 
CVCC 1396 (eaeA+ bfpA+, 384bp and 324bp); Lane 3, 
ZR1 (16S rRNA PCR +, 584bp); Lane 4, CVCC 1396 
(16S rRNA PCR+, 584bp).
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enteropathogenic E. coli (EPEC) O antisera. The results 
of antimicrobial susceptibility tests demonstrated that 
ZR1  was sensitive to quinolones, aminoglycosides and 
the third- or fourth-generation cephalosporins. However, 
ZR1  was resistant to the first- and second-generation 
cephalosporins, sulphamethoxazole-trimethoprim (SXT), 
tetracycline and ampicillin (Table  1). The results of VP, 
H2S, citrate and sucrose tests were negative, but the tests 
on lactose and D-sorbitol were positive. 
Isolation and morphology of bacteriophage ZRP1
The ZRP1 plaques were round and clear with 0.5 to 1 mm 
in diameter on average. Under transmission electron 
microscopy, the virion (Figure 2a, 2b) had a hexagonal 
head (65 nm in diameter) and a contractile tail (95 nm in 
length and 10 nm in width) with a sheath (15 nm in width 
in contraction).
Latent period, burst size and rate of phage-
resistant mutation
The one-step growth curve of bacteriophage ZRP1 was 
shown in Figure 3. Latent period was defined as 
the timeframe between the onset of incubation and 
the initiation of rise period. It was estimated to be 
approximately 25  to 30  min in the 2 tests, and the 
mean burst size of ZRP1 was 144±31 (mean± standard 
deviation [SD]) PFU per infected cell. The mean fraction of 
ZR1 resistant to ZRP1 was 7×10–5±4×10–5 (mean±SD).
 
Figure 2: Transmission electron microscopic 
appearance of bacteriophage ZRP1. (a) Electron 
micrograph of a phage ZRP1. (b) Electron micrograph 
of a phage ZRP1 showing its contractile tail.
a)
b)
Figure 3: One-step growth curve of phage ZRP1 on E. coli ZR1. Titres at different sample times are shown in plaque-
forming unit (PFU)/mL. Each point is the mean of 2 independent experiments, and the bar represents standard 
deviation.
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Growth inhibition of E. coli at different MOIs in vitro
The growth of E. coli ZR1  without infection reached stationary phase in 3  h, but the growth of ZR1  infected 
with ZRP1  at any MOI was retarded. The result of One-Way ANOVA and LSD showed significant differences 
between the non-infected group and infected groups from 1 h to 7 h post-infection (P=0.000). At MOI 0.01, the 
OD600 started to decrease after 1 h but increased again at 4 h post-infection. However, OD600 values of MOI 0.1, 
1 or 10 remained stable before 5 h post infection but quickly increased after 6 h (Figure 4). The statistical results 
indicated that OD600 values were significantly higher in the MOI 0.01 group than in other MOIs before 6 hr post-
infection (P<0.05). 
Efficacy of phage therapy in vivo
The experiment was finished at 14 h after the infection and all rabbits died except 2 which survived. One of them 
was treated with MOI 10 and the other was treated with MOI 0.1. However, both rabbits were dying at that time 
and showed symptoms such as trembling, depression and clenching teeth tightly. They were humanely killed to 
alleviate the pain they suffered. Statistical analysis showed that survival times were significantly different between 
the control group and phage-treated groups, but no significant difference was found among phage-treated groups 
(Table 2). Necropsy of rabbits in the experiment revealed haemorrhages in the caecal and rectal mucosae. Results 
of biochemical reactions and PCR identification of E. coli re-isolated from all rabbits were as the same as those 
for ZR1. 
Figure 4: OD600 development of E. coli ZR1 (1×10
8 colony forming units/mL at the beginning) infected with or without 
ZRP1 at different MOIs.  Each point on the figure is shown as mean±standard deviation of 3 replicates. The initial 
OD600 value was 0.120. OD: Optical density; MOI: Multiplicity of infection.   Control;  MOI 10;  MOI 1; 
 MOI 0.1;  MOI 0.01.
Table 2: Survival time of rabbits treated with or without different levels of bacteriophage (mean±standard deviation).
Control MOI 0.1 MOI 1 MOI 10
Weight (kg) 0.87±0.25 0.90±0.26 0.87±0.26 0.88±0.26
Survival Time (h) 6.25±0.16a 8.37±0.93b 9.50±1.12b 9.38±1.17b
a,bMeans with no common superscript letter differ significantly (P<0.05).
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DISCUSSION
E. coli ZR1 should be classified as atypical EPEC for its eae+ bfp- genetic profile (Nataro and Kaper, 1998). It can 
adhere to the enterocyte membrane, producing the characteristic attaching and effacing (A/E) lesion (Kaper et al., 
2004) and therefore be a common cause of diarrhoea in rabbits (Penteado, et al., 2002; Swennes, et al., 2012). 
Most atypical EPEC strains were reported belonging to traditional EPEC serogroups such as O26, O55, O86, O111, 
O119, O125 and O128, but quite a few strains could not agglutinate in the usual set of O antisera (Trabulsi, et al., 
2002). 
Ampicillin and piperacillin could be inactivated by β-lactamase produced by penicillin-resistant E. coli, and 
resistances to tetracycline or SXT were generally found in diarrhoeagenic E. coli in south China (Zhang et al., 
2017) which might be induced by a selective pressure of antimicrobial misuse. 
Analysis of the TEM images suggested that bacteriophage ZRP1 belongs to the family Myoviridae for its hexagonal 
head and contractile sheathed tail (Zhang et al., 2013). Burst size was considered as a critical parameter that 
affected phage therapy (Skurnik and Strauch, 2006) because the more the progeny were released, the more 
advantage the phage had. The burst size of ZRP1 was larger than those of coliphages such as the Myoviridae 
family Bp7 (Zhang et al., 2013), Siphoviridae family ECP4 (Lee and Park, 2013) and Podoviridae family EC200pp 
(Pouillot, et al., 2012). 
It was highly likely that phage-resistant mutants would emerge in a bacterial population of 106 to 108 (Skurnik and 
Strauch, 2006). Our result was similar to those reporting rates such as from 3×10–4 to 1.9×10–6 (O’Flynn et al., 
2006) or 7×10–6 (Pouillot et al., 2012). 
OD600-based assay was commonly used to assess or to select bacteriophages before attempting in animal trials 
(Alam et al., 2011; Han et al., 2013). Obviously, in vitro experiments demonstrated that using ZRP1 above a certain 
MOI threshold immediately inhibited the growth of host bacteria, and the results indicate that ZRP1 performed 
better against ZR1 at a higher MOI than a lower one. However, the regrowth observed after several hours indicated 
the substitution of phage-resistant bacteria (Tanji, et  al., 2004). Intravenous injection of pathogenic E. coli 
ZR1 caused haemorrhages of the large intestine and led to a systemic infection involving the liver. Bacteriophages 
injected intravenously could rescue experimental animals (Cerveny et  al., 2002) and MOIs between 0.01  and 
100 are often used in in vivo experiments (Mai Huong Ly-Chatain, 2014). A dose-response effect was observed 
(Wang et al., 2005) and it was suggested that phage should be given as large a dose as possible if it were not for 
side effects in phage therapy (Payne and Jansen, 2003). Nevertheless, increasing the phage level did not show a 
significant advantage in our in vivo experiment. Unfortunately, although survival time of rabbits was prolonged by 
phage treatment, almost all rabbits died in the experiment. One possible explanation might be that the infection 
was too serious to save. Phage-resistant mutants should also be taken into account, as they might cause the 
failure of phage therapy (Smith and Huggins, 1983).
In general, ZRP1 proved to be effective against ZR1 in vitro and in vivo. This paves the way for further research into 
the efficacy of ZRP1, considering different infecting doses and pathways of E. coli ZR1.
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